Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has issued an update.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that non-executive director Wei Yiliang has resigned from the board, and from his roles on the Audit Committee and the Strategy Development Committee, effective 31 December 2025, citing other work arrangements. The company stressed that Wei has no disagreement with the board, that his departure will not reduce the board below its statutory quorum or disrupt normal operations, and that the board thanked him for his contributions during his tenure, signalling a routine governance change with limited immediate impact on the company’s operations or regulatory standing.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong, operating in the pharmaceuticals and biotechnology sector. The company is governed by a board comprising executive, non-executive, independent non-executive and employee directors, reflecting a typical governance structure for a Hong Kong–listed mainland Chinese pharma group.
Average Trading Volume: 931,127
Technical Sentiment Signal: Hold
Current Market Cap: HK$13.85B
See more data about 2315 stock on TipRanks’ Stock Analysis page.